Yunjie Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yunjie Sun has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Anil K. Sood
13 shared publications- Cristina Ivan
Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
13 shared publications Heather J. Dalton
13 shared publicationsLingegowda S. Mangala
13 shared publications- Rebecca Ann Previs
LabCorp, Durham, NC
13 shared publications - Robert L. Coleman
Texas Oncology, Gynecologic Oncology, The Woodlands, TX, USA
13 shared publications
Latest Publications
- 25 February 2024
- Published by Springer Nature
- p. 756-765
Construction and Analysis of IPTV User Profile Based on Multimedia Design
- 25 February 2024
- Published by Springer Nature
- p. 756-765
Construction and Analysis of IPTV User Profile Based on Multimedia Design
- 2 February 2024
- Published by Springer Nature
- p. 540-550
Development Research on Openness Evaluation Factors for Pocket Parks
- 2 February 2024
- Published by Springer Nature
- p. 540-550
Development Research on Openness Evaluation Factors for Pocket Parks
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer
Supplementary Figure 1. In vitro effects of PR silencing on onapristone sensitivity in PR-high-expressing uterine cancer cell line (Ishikawa). Supplementary Figure 2. In vitro effects of onapristone and trametinib in PR-weak-expressing uterine cancer cell line (SKUT2). Supplementary Figure 3. In vivo effects of therapy with onapristone in uterine cancer model. Supplementary Figure 4. In vivo effect of onapristone, trametinib, and the combination of both drugs on total PR expression in the ISHIKAWA model.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer
Supplementary Figure 1. In vitro effects of PR silencing on onapristone sensitivity in PR-high-expressing uterine cancer cell line (Ishikawa). Supplementary Figure 2. In vitro effects of onapristone and trametinib in PR-weak-expressing uterine cancer cell line (SKUT2). Supplementary Figure 3. In vivo effects of therapy with onapristone in uterine cancer model. Supplementary Figure 4. In vivo effect of onapristone, trametinib, and the combination of both drugs on total PR expression in the ISHIKAWA model.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer
Supplementary Figure 1. In vitro effects of PR silencing on onapristone sensitivity in PR-high-expressing uterine cancer cell line (Ishikawa). Supplementary Figure 2. In vitro effects of onapristone and trametinib in PR-weak-expressing uterine cancer cell line (SKUT2). Supplementary Figure 3. In vivo effects of therapy with onapristone in uterine cancer model. Supplementary Figure 4. In vivo effect of onapristone, trametinib, and the combination of both drugs on total PR expression in the ISHIKAWA model.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer
Supplementary Figure 1. In vitro effects of PR silencing on onapristone sensitivity in PR-high-expressing uterine cancer cell line (Ishikawa). Supplementary Figure 2. In vitro effects of onapristone and trametinib in PR-weak-expressing uterine cancer cell line (SKUT2). Supplementary Figure 3. In vivo effects of therapy with onapristone in uterine cancer model. Supplementary Figure 4. In vivo effect of onapristone, trametinib, and the combination of both drugs on total PR expression in the ISHIKAWA model.
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Notch3 Pathway Alterations in Ovarian Cancer
PDF file - 96K, Notch Pathway Alterations in Patients with HGS-OvCa.
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Notch3 Pathway Alterations in Ovarian Cancer
PDF file - 96K, Notch Pathway Alterations in Patients with HGS-OvCa.
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Notch3 Pathway Alterations in Ovarian Cancer
PDF file - 55K, Correlation between key transcription factors and Notch3 overexpression.
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Notch3 Pathway Alterations in Ovarian Cancer
PDF file - 55K, Correlation between key transcription factors and Notch3 overexpression.
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1 - 5 from Notch3 Pathway Alterations in Ovarian Cancer
PDF file - 765K, Overall Survival (OS) Analysis in Patients With High-Grade Serous Ovarian Cancer HGS-OvCa (S1); In Vitro Functional Studies of Notch3 siRNA or GSI and combined with Paclitaxel in OvCa Cells (S2); qRT-PCR Analysis of Expression of Gamma-Secretase Complex in Ovarian Cancer Cells (S3); In vitro effects of blocking endocytosis on Jagged-1/Notch3 pathway in cancer cells (S4); In vivo study of Notch3 siRNA in orthotopic mouse models of ovarian cancer (S5).
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1 - 5 from Notch3 Pathway Alterations in Ovarian Cancer
PDF file - 765K, Overall Survival (OS) Analysis in Patients With High-Grade Serous Ovarian Cancer HGS-OvCa (S1); In Vitro Functional Studies of Notch3 siRNA or GSI and combined with Paclitaxel in OvCa Cells (S2); qRT-PCR Analysis of Expression of Gamma-Secretase Complex in Ovarian Cancer Cells (S3); In vitro effects of blocking endocytosis on Jagged-1/Notch3 pathway in cancer cells (S4); In vivo study of Notch3 siRNA in orthotopic mouse models of ovarian cancer (S5).
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Notch3 Pathway Alterations in Ovarian Cancer
PDF file - 183K, The siRNA and Primer Sequences.
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Notch3 Pathway Alterations in Ovarian Cancer
PDF file - 183K, The siRNA and Primer Sequences.
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Notch3 Pathway Alterations in Ovarian Cancer
PDF file - 65K, Microarray Analysis of Significantly Down- regulated Genes in OVCAR3 cells With or Without Notch3 Silencing.
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Notch3 Pathway Alterations in Ovarian Cancer
PDF file - 65K, Microarray Analysis of Significantly Down- regulated Genes in OVCAR3 cells With or Without Notch3 Silencing.